Inicio
Proyectos y Estudios
ESTUDIO DE EXTENSION DE OCHO MESES, DOBLE CIEGO, PARA LA RECOPLILACION DE LOS DATOS DE DURABILIDAD DE LA EFICACIA Y DATOS ADICIONALES DE SEGURIDAD EN PACIENTES CON ARTRITIS REUMATOIDE JUVENIL QUE COMPLETAN EL ESTUDIO COMPARATIVO DOBLE CIEGO HWA486/3503 DE LEFLUMONIDA VERSUS METOTREXATO.

ESTUDIO DE EXTENSION DE OCHO MESES, DOBLE CIEGO, PARA LA RECOPLILACION DE LOS DATOS DE DURABILIDAD DE LA EFICACIA Y DATOS ADICIONALES DE SEGURIDAD EN PACIENTES CON ARTRITIS REUMATOIDE JUVENIL QUE COMPLETAN EL ESTUDIO COMPARATIVO DOBLE CIEGO HWA486/3503 DE LEFLUMONIDA VERSUS METOTREXATO.

Datos básicos

Protocolo:: HWA486/3504
EUDRACT:: NO PROCEDE
NCT:
Centro:
Año de incio:
Año de finalización:

ENSAYO CLÍNICO

Documentos

No hay documentos

Participantes

Inmaculada Calvo Penadés

Investigador Principal

Grupos

Reumatología Pediátrica

Investigador establecido

Inmaculada Calvo Penadés

Financiadores - Promotores

AVENTIS PHARMACEUTICALS

Resultados del Ensayo Clínico

Publicaciones en Revistas 22

Aicardi-Goutieres syndrome type 6: report of ADAR variant and clinical outcome after ruxolitinib treatment in the neonatal period

Gabaldon-Albero, Alba; (...); Martinez, Francisco

Article. 10.1186/s12969-024-01036-5. 2024

CLINICAL VARIABILITY IN PATIENTS DIAGNOSED OF JUVENILE IDIOPATHIC ARTHRITIS WITH POSITIVE AND NEGATIVE ANTINUCLEAR ANTIBODIES (ANA)

Torrat Noves, A. M.; (...); Roman Ivorra, J. A.

Meeting Abstract. 10.1136/annrheumdis-2023-eular.5203. 2023

Current situation of osteogenesis imperfecta in Spain: results from a Delphi study

Sagastizabal, Belen; (...); Bou, Rosa

Article. 10.1186/s13023-024-03248-0. 2024

Childhood-Onset Non-Infectious Uveitis in the "Biologic Era". Results From Spanish Multicenter Multidisciplinary Real-World Clinical Settings.

Mesa-Del-Castillo P; (...); Sánchez Sevila JL

Article. 10.1080/09273948.2024.2336609. 2024

Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-alpha inhibitor initiation in children in Spain.

Calzada-Hernandez, Joan; (...); Noguera-Julian, Antoni

Article. 10.1007/s00431-022-04640-3. 2022

HOW TO DIAGNOSE: JUVENILE PSORIATIC ARTHRITIS. MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY IN CHILDREN WITH SUSPECTED DIAGNOSIS

Palmou-Fontana, N.; (...); Collado, P.

Meeting Abstract. 10.1136/annrheumdis-2023-eular.1883. 2023

Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review.

Salgado E; (...); Gomez-Reino JJ

Article. 10.1016/j.semarthrit.2021.10.004. 2022

Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial.

Jeyaratnam J; (...); Frenkel J

Article. 10.1093/rheumatology/keab696. 2021

Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.

Brunner, Hermine I; (...); De Benedetti, Fabrizio

Article. 10.1093/rheumatology/keae180. 2024

Long-term efficacy/safety of canakinumab in patients with tumor necrosis factor receptor-associated periodic syndrome: results from a phase III trial.

Gattorno, Marco; (...); Lachmann, Helen

Article. 10.1002/art.42695. 2023

Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept.

Brunner, Hermine I; (...); Ruperto, Nicolino

Article. 10.1002/acr.25156. 2023

Multidisciplinary consensus on the use of hydroxychloroquine in patients with systemic lupus erythematosus

Rua-Figueroa, Inigo; (...); Calvo Alen, Jaime

Article. 10.1016/j.reuma.2024.03.005. 2024

MUSCULOSKELETAL INVOLVEMENT IMPAIRS QUALITY OF LIFE IN JUVENILE PSORIATIC ARTHRITIS

Collado, P.; (...); Lopez Robledillo, J. C.

Meeting Abstract. 10.1136/annrheumdis-2023-eular.3892. 2023

Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial

Brunner, Hermine; (...); Wilde, Paul

Meeting Abstract. 2023

Real-World Health Care Outcomes and Costs Among Patients With Juvenile Idiopathic Arthritis in Spain.

Antón J; (...); Calvo Penadés I

Article. 10.36469/001c.85088. 2023

Real-world psychosocial impact among patients with juvenile idiopathic arthritis and families in Spain

Penades, Inmaculada Calvo; (...); Anton, Jordi

Article. 10.1186/s12969-024-01035-6. 2024

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

Brunner, Hermine, I; (...); Ruperto, Nicolino

Article. 10.1136/ard-2022-222849. 2022

Secukinumab Treatment in Children and Adolescents with Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Efficacy and Safety Results from a Phase 3 Study

Brunner, Hermine; (...); Ruperto, Nicolino

Meeting Abstract. 2021

USE OF HEALTHCARE RESOURCES AND COST ASSOCIATED RELATED TO JUVENILE IDIOPATHIC ARTHRITIS IN SPAIN: THE ITACA-OR REAL-WORLD STUDY

Peral, C.; (...); Calvo, I

Meeting Abstract. 2022

Validity and reliability of four parent/patient reported outcome measures for juvenile idiopathic arthritis remote monitoring.

van Dijkhuizen EHP; (...); Paediatric Rheumatology International Trials Organisation (PRINTO)

Article. 10.1002/acr.24855. 2022

What drives the decision to optimise biological treatment in children and youngsters with juvenile idiopathic arthritis? A discrete-choice experiment

Murias, Sara; (...); Anton, Jordi

Article. 10.1016/j.reuma.2021.12.003. 2023

What drives the decision to optimise biological treatment in children and youngsters with juvenile idiopathic arthritis? A discrete-choice experiment.